NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke.
Auteur : Merino-Zamorano C, HernÃ¡ndez-Guillamon M, Jullienne A, Le Béhot A, Bardou I, Parés M, FernÃ¡ndez-Cadenas I, Giralt D, Carrera C, Ribó M, Vivien D, Ali C, Rosell A, Montaner J
Année : 2015
Journal : Stroke 1524-4628
PubMed Id : 25503547
Despite the effectiveness of recombinant tissue-type plasminogen activator (r-tPA) during the acute phase of ischemic stroke, the therapy remains limited by a narrow time window and the occurrence of occasional vascular side effects, particularly symptomatic hemorrhages. Our aim was to investigate the mechanisms underlying the endothelial damage resulting from r-tPA treatment in ischemic-like conditions.